Delcath Systems (NASDAQ:DCTH) rose 6.78% on June 23, 2026, as HEPZATO sales outlook sustained commercial momentum, with shares closing at $12.29.

Key Highlights

  • Rose 6.78%: Delcath Systems closed at $12.29 on June 23 after moving $0.78 per share.
  • Catalyst: During the session, HEPZATO sales outlook sustained commercial momentum.
  • Company: Delcath Systems commercialises HEPZATO, a liver-directed chemotherapy delivery system for metastatic uveal melanoma.
  • Session: The stock finished at $12.29, while the available company record showed a disclosed catalyst for the move.

Delcath Systems (NASDAQ:DCTH) rose 6.78% on June 23, 2026, closing at $12.29 after a $0.78 per-share move. The session’s advance came as HEPZATO sales outlook sustained commercial momentum, based on the available company disclosures and trading context.

The gain extended optimism from Delcath's strong first-quarter performance and management's expectation for at least $100 million in full-year 2026 revenue from its HEPZATO KIT liver-directed chemotherapy delivery system. HEPZATO received FDA approval in 2023 for metastatic uveal melanoma, and commercial uptake has been gradually accelerating.

Delcath Systems commercialises HEPZATO, a liver-directed chemotherapy delivery system for metastatic uveal melanoma.

No additional reimbursement decision or clinical update accompanied the session's move.

The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.

The shares closed at $12.29 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.

For the June 23 close, the defining facts were the 6.78% advance, the $12.29 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.